Hospital
Fresno Community Hospital and Medical Center
Fresno Community Hospital and Medical Center was paid $37.97M by Medicaid between Jan 2018 and Dec 2024, across 682 billing codes. Its largest line is 0450, Emergency room services — 18% of everything it billed.
33Billing provider infoFRESNO COMMUNITY HOSPITAL AND MEDICAL CENTER
FRESNO, CA 93721
FRESNO, CA 93721
33aNPI1104906569assigned 10/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.97M
24GClaims4,255,231
24DCodes billed682
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#76 of 410
Median peer was paid$6.90M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 850,024 | $9.74M | |
| 2019 | 695,264 | $6.20M | |
| 2020 | 511,594 | $3.04M | |
| 2021 | 542,213 | $4.17M | |
| 2022 | 546,927 | $4.40M | |
| 2023 | 591,574 | $5.55M | |
| 2024incomplete | 517,635 | $4.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 18% | 294,185 | 248,579 | $6.83M |
| J3490 | Unclassified drugs | 12% | 200,945 | 78,920 | $4.49M |
| 99199 | Unlisted special service, procedure or report | 11% | 46,111 | 43,952 | $4.12M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 9.5% | 42,665 | 15,537 | $3.62M |
| 80047 | 6.6% | 175,041 | 159,589 | $2.52M | |
| Z7502 | 2.6% | 26,185 | 25,770 | $988K | |
| Z9725 | 1.7% | 15,420 | 15,334 | $663K | |
| 0360 | 1.4% | 14,354 | 12,383 | $549K | |
| G0378 | Hospital observation service, per hour | 1.4% | 1,848 | 894 | $538K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.3% | 5,382 | 4,619 | $502K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 35,019 | 33,872 | $448K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 35,008 | 33,861 | $428K |
670 more codes
| 0761 | 1.1% | 39,642 | $414K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 47,587 | $401K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.0% | 170,848 | $396K |
| Z7500 | <1% | 10,964 | $373K | |
| 93325 | <1% | 6,282 | $354K | |
| 0206 | <1% | 569 | $327K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 267,298 | $308K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 38,852 | $295K |
| 96112 | <1% | 1,690 | $273K | |
| 93320 | <1% | 5,271 | $239K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 39,472 | $226K |
| Z4300 | <1% | 2,161 | $222K | |
| 90999 | Dialysis (unlisted procedure) | <1% | 6,139 | $206K |
| 0510 | <1% | 11,900 | $192K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 30,006 | $190K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 314 | $183K |
| Z4304 | <1% | 2,156 | $166K | |
| 96379 | <1% | 2,282 | $165K | |
| 97139 | <1% | 26,752 | $161K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 84,815 | $160K |
| Z7610 | <1% | 19,653 | $160K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 531 | $148K |
| 86850 | <1% | 23,794 | $136K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15,313 | $121K |
| 86780 | <1% | 37,921 | $114K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 43,823 | $114K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17,193 | $107K |
| A4217 | Sterile water/saline, 500 ml | <1% | 3,930 | $107K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,457 | $107K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,125 | $102K |
| 99283 | Emergency room visit (moderate) | <1% | 5,038 | $96K |
| 81001 | <1% | 106,878 | $92K | |
| 0160 | <1% | 18,688 | $89K | |
| 95911 | <1% | 4,625 | $86K | |
| 0710 | <1% | 8,730 | $86K | |
| 97750 | <1% | 10,336 | $85K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 34,317 | $81K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,532 | $80K |
| 0270 | <1% | 290,884 | $79K | |
| 81025 | <1% | 15,010 | $79K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,605 | $78K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 37,001 | $77K |
| 97799 | <1% | 9,481 | $76K | |
| 0760 | <1% | 29,129 | $74K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51,428 | $72K |
| 93975 | <1% | 4,250 | $72K | |
| 96113 | <1% | 988 | $71K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 7,491 | $70K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 506 | $64K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 16,938 | $63K |
| 73130 | <1% | 11,088 | $59K | |
| 73610 | <1% | 9,682 | $59K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,108 | $58K |
| 71045 | Radiologic examination, chest; single view | <1% | 32,548 | $58K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,671 | $56K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,528 | $56K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,502 | $55K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,370 | $55K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 30,951 | $54K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,207 | $53K |
| 87653 | <1% | 11,047 | $50K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,151 | $50K |
| 80053 | Comprehensive metabolic panel | <1% | 54,181 | $50K |
| 84702 | <1% | 33,258 | $49K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,768 | $48K |
| 86696 | <1% | 12,660 | $48K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,363 | $48K |
| 86900 | <1% | 27,366 | $46K | |
| 86762 | <1% | 11,580 | $45K | |
| 0250 | <1% | 6,239 | $45K | |
| 95886 | <1% | 5,963 | $45K | |
| 80076 | <1% | 68,559 | $44K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 38,266 | $44K |
| 96367 | <1% | 4,054 | $43K | |
| 84484 | <1% | 51,527 | $43K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,990 | $43K |
| 0636 | <1% | 1,171 | $43K | |
| 73630 | <1% | 10,793 | $43K | |
| 95816 | <1% | 4,650 | $42K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 570 | $42K |
| 87340 | <1% | 15,694 | $42K | |
| 73564 | <1% | 9,329 | $39K | |
| 96111 | <1% | 339 | $37K | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,286 | $37K |
| 76825 | <1% | 1,327 | $36K | |
| 73110 | <1% | 6,850 | $35K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,549 | $35K |
| 76827 | <1% | 1,219 | $34K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,059 | $33K |
| 71250 | <1% | 783 | $32K | |
| 94729 | <1% | 6,516 | $32K | |
| 94060 | <1% | 6,546 | $32K | |
| 73030 | <1% | 7,579 | $31K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 853 | $31K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,462 | $30K |
| 86480 | <1% | 1,970 | $29K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 243 | $29K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 23,126 | $29K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,065 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,745 | $27K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 923 | $26K |
| 0324 | <1% | 777 | $26K | |
| Z4302 | <1% | 2,098 | $25K | |
| 72141 | <1% | 628 | $25K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 1,169 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,947 | $25K |
| J9310 | Injection, rituximab, 100 mg | <1% | 61 | $24K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,918 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 8,759 | $24K |
| 59025 | Fetal non-stress test | <1% | 2,073 | $23K |
| 86481 | <1% | 7,281 | $22K | |
| 76830 | Ultrasound, transvaginal | <1% | 7,165 | $22K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 515 | $22K |
| 83690 | <1% | 51,459 | $22K | |
| 96415 | <1% | 2,585 | $21K | |
| 87088 | <1% | 20,193 | $20K | |
| 87536 | <1% | 6,800 | $20K | |
| 82962 | <1% | 18,960 | $19K | |
| S9460 | Diabetic management program, nurse visit | <1% | 343 | $19K |
| 86901 | <1% | 27,367 | $19K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,475 | $19K |
| 85610 | <1% | 30,140 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,309 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,398 | $17K |
| 76770 | <1% | 2,755 | $17K | |
| 85027 | <1% | 18,731 | $17K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,418 | $17K |
| 97165 | <1% | 2,236 | $17K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,618 | $16K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 28 | $16K |
| 83880 | <1% | 15,959 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,051 | $16K |
| 99284 | Emergency room visit (serious) | <1% | 1,567 | $16K |
| 94726 | <1% | 4,315 | $15K | |
| 73502 | <1% | 3,334 | $15K | |
| 74170 | <1% | 782 | $15K | |
| 80061 | Lipid panel | <1% | 28,797 | $14K |
| 87632 | <1% | 3,153 | $14K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,593 | $14K |
| 93971 | <1% | 3,029 | $14K | |
| 95885 | <1% | 1,204 | $14K | |
| 93970 | <1% | 914 | $14K | |
| 70486 | <1% | 2,116 | $14K | |
| 73080 | <1% | 3,694 | $14K | |
| 86592 | <1% | 7,452 | $14K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 22,029 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 17,910 | $14K |
| 86695 | <1% | 4,421 | $14K | |
| 72126 | <1% | 1,911 | $13K | |
| 73590 | <1% | 5,046 | $13K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 2,873 | $13K |
| 72100 | <1% | 4,074 | $12K | |
| 96417 | <1% | 1,070 | $12K | |
| Z4308 | <1% | 477 | $12K | |
| 86361 | <1% | 6,533 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,066 | $12K |
| 0750 | <1% | 44 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 11,661 | $11K |
| 91200 | <1% | 2,294 | $11K | |
| Z7506 | <1% | 124 | $11K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,700 | $11K |
| 0300 | <1% | 1,044 | $11K | |
| 70491 | <1% | 714 | $11K | |
| 16020 | <1% | 1,293 | $11K | |
| 87210 | <1% | 19,021 | $11K | |
| 76536 | <1% | 1,285 | $11K | |
| 0272 | <1% | 791 | $11K | |
| 93458 | <1% | 332 | $11K | |
| 73552 | <1% | 2,585 | $11K | |
| 73090 | <1% | 3,676 | $10K | |
| 83970 | <1% | 2,580 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,329 | $10K |
| 94010 | <1% | 3,312 | $10K | |
| 93017 | <1% | 1,569 | $10K | |
| 72110 | <1% | 1,541 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,062 | $9K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 592 | $9K |
| 93880 | <1% | 411 | $9K | |
| 83735 | <1% | 17,976 | $9K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 736 | $9K |
| Z4301 | <1% | 267 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,350 | $9K |
| Z4307 | <1% | 329 | $9K | |
| 90715 | <1% | 6,800 | $9K | |
| 72050 | <1% | 1,772 | $8K | |
| 36821 | <1% | 233 | $8K | |
| 74018 | <1% | 3,267 | $8K | |
| 77334 | <1% | 125 | $8K | |
| 97166 | <1% | 236 | $8K | |
| 82950 | <1% | 8,701 | $8K | |
| 94727 | <1% | 942 | $8K | |
| J2778 | Injection, ranibizumab, 0.1 mg | <1% | 38 | $8K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 1,777 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,598 | $8K |
| 90686 | <1% | 1,410 | $8K | |
| 76642 | <1% | 535 | $8K | |
| 90734 | <1% | 277 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,168 | $7K |
| 82247 | <1% | 6,025 | $7K | |
| 71020 | <1% | 1,755 | $7K | |
| 97010 | <1% | 9,682 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,075 | $7K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 123 | $7K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 81 | $7K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,589 | $7K |
| 94760 | <1% | 2,679 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 866 | $7K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 399 | $7K |
| 86593 | <1% | 3,545 | $7K | |
| 87503 | <1% | 8,755 | $7K | |
| 80074 | <1% | 2,705 | $7K | |
| 87506 | <1% | 1,142 | $6K | |
| 84703 | <1% | 17,423 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 186 | $6K |
| 77336 | <1% | 374 | $6K | |
| 70544 | <1% | 250 | $6K | |
| 0352 | <1% | 44 | $6K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 20 | $6K |
| 76801 | <1% | 4,317 | $6K | |
| 97803 | <1% | 2,775 | $6K | |
| 86803 | <1% | 8,847 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 11,108 | $6K |
| 83615 | <1% | 6,499 | $6K | |
| 94618 | <1% | 1,899 | $6K | |
| 72170 | <1% | 2,972 | $6K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 3,187 | $6K |
| 82728 | <1% | 7,311 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,353 | $6K |
| 85730 | <1% | 8,634 | $6K | |
| 36832 | <1% | 203 | $6K | |
| 0403 | <1% | 94 | $6K | |
| 73060 | <1% | 2,048 | $6K | |
| 86003 | <1% | 430 | $6K | |
| 84436 | <1% | 3,687 | $5K | |
| 0301 | <1% | 309 | $5K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,507 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 227 | $5K |
| 77412 | <1% | 771 | $5K | |
| 73600 | <1% | 123 | $5K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 383 | $5K |
| J0897 | Injection, denosumab, 1 mg | <1% | 55 | $5K |
| 87081 | <1% | 3,275 | $5K | |
| Z4311 | <1% | 429 | $5K | |
| 72131 | <1% | 956 | $5K | |
| 73140 | <1% | 726 | $5K | |
| 70496 | <1% | 834 | $5K | |
| 82746 | <1% | 4,827 | $5K | |
| 84466 | <1% | 7,979 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 508 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,283 | $5K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 180 | $5K |
| 70498 | <1% | 877 | $5K | |
| 83655 | <1% | 5,658 | $5K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,331 | $5K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 557 | $5K |
| 90649 | <1% | 71 | $5K | |
| 76870 | <1% | 1,300 | $5K | |
| 0762 | <1% | 1,173 | $5K | |
| 96416 | <1% | 320 | $4K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 124 | $4K |
| 73562 | <1% | 1,374 | $4K | |
| 82607 | <1% | 8,409 | $4K | |
| 96411 | <1% | 472 | $4K | |
| 82140 | <1% | 2,762 | $4K | |
| 72072 | <1% | 690 | $4K | |
| T1014 | Telehealth transmission, per minute, professional services bill separately | <1% | 3,842 | $4K |
| Z4312 | <1% | 323 | $4K | |
| 87077 | <1% | 6,687 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,084 | $4K |
| 91037 | <1% | 347 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,457 | $4K |
| 70355 | <1% | 777 | $4K | |
| 86140 | <1% | 9,621 | $4K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 71 | $4K |
| 82274 | <1% | 4,140 | $4K | |
| 88342 | <1% | 559 | $4K | |
| 93308 | <1% | 386 | $4K | |
| 87186 | <1% | 5,924 | $3K | |
| 72040 | <1% | 575 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,682 | $3K |
| 84100 | <1% | 12,703 | $3K | |
| 82570 | <1% | 12,393 | $3K | |
| 93990 | <1% | 53 | $3K | |
| 72190 | <1% | 303 | $3K | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 1,499 | $3K |
| 94664 | <1% | 3,577 | $3K | |
| 94644 | <1% | 2,788 | $3K | |
| 74240 | <1% | 356 | $3K | |
| 0320 | <1% | 479 | $3K | |
| 90732 | <1% | 124 | $3K | |
| 84550 | <1% | 6,376 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,459 | $3K |
| 83605 | <1% | 9,229 | $3K | |
| 70487 | <1% | 132 | $3K | |
| 99152 | <1% | 537 | $3K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 44 | $3K |
| 84439 | <1% | 8,306 | $3K | |
| 82565 | <1% | 5,533 | $3K | |
| 86923 | <1% | 1,114 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,128 | $3K |
| J9312 | Injection, rituximab, 10 mg | <1% | 30 | $3K |
| 83540 | <1% | 8,276 | $3K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 219 | $3K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 305 | $3K |
| 87040 | <1% | 3,115 | $3K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 2,062 | $3K |
| 87430 | <1% | 3,236 | $3K | |
| 86235 | <1% | 1,248 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,040 | $3K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,975 | $3K |
| 96368 | <1% | 364 | $3K | |
| 82731 | <1% | 813 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 85 | $3K |
| 84460 | <1% | 4,265 | $2K | |
| 91010 | <1% | 347 | $2K | |
| 77290 | <1% | 77 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,958 | $2K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 297 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 613 | $2K |
| 82533 | <1% | 2,337 | $2K | |
| 90746 | <1% | 113 | $2K | |
| 70360 | <1% | 507 | $2K | |
| S9455 | Diabetic management program, group session | <1% | 73 | $2K |
| 73700 | <1% | 286 | $2K | |
| 97162 | <1% | 1,343 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,825 | $2K |
| 82784 | <1% | 1,239 | $2K | |
| 84450 | <1% | 4,083 | $2K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 268 | $2K |
| 87070 | <1% | 2,241 | $2K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 884 | $2K |
| 0370 | <1% | 651 | $2K | |
| 0410 | <1% | 53 | $2K | |
| 84156 | <1% | 7,770 | $2K | |
| 94728 | <1% | 622 | $2K | |
| 92523 | <1% | 67 | $2K | |
| 85379 | <1% | 5,929 | $2K | |
| 82951 | <1% | 2,594 | $2K | |
| 80069 | <1% | 1,909 | $2K | |
| 72070 | <1% | 687 | $2K | |
| 82550 | <1% | 3,326 | $2K | |
| 82105 | <1% | 1,640 | $2K | |
| 0430 | <1% | 28 | $2K | |
| 80051 | <1% | 735 | $2K | |
| 82670 | <1% | 1,655 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,241 | $2K |
| 95909 | <1% | 205 | $2K | |
| 0401 | <1% | 16 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,970 | $2K |
| 90677 | <1% | 106 | $1K | |
| 89060 | <1% | 2,299 | $1K | |
| 81003 | <1% | 1,328 | $1K | |
| 92521 | <1% | 438 | $1K | |
| 96523 | <1% | 136 | $1K | |
| 86038 | <1% | 2,556 | $1K | |
| 85651 | <1% | 9,486 | $1K | |
| 99221 | <1% | 144 | $1K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 231 | $1K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 203 | $1K |
| 82803 | <1% | 770 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 153 | $1K |
| 84153 | <1% | 650 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,263 | $1K |
| 84403 | <1% | 1,942 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,793 | $1K |
| 84481 | <1% | 2,328 | $1K | |
| 95913 | <1% | 15 | $1K | |
| Z4310 | <1% | 106 | $1K | |
| 85018 | <1% | 420 | $1K | |
| 77300 | <1% | 72 | $1K | |
| 72114 | <1% | 318 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 471 | $1K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 235 | $1K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 243 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,839 | $1K |
| 86706 | <1% | 3,527 | $1K | |
| 87075 | <1% | 1,295 | $1K | |
| 72128 | <1% | 351 | $1K | |
| 84402 | <1% | 1,461 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 4,859 | $1K |
| 90670 | <1% | 65 | $1K | |
| 84146 | <1% | 2,418 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 738 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 8,650 | $1K |
| 82248 | <1% | 2,803 | $1K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 419 | $1K |
| 86635 | <1% | 656 | $1K | |
| 93000 | <1% | 72 | $1K | |
| 82785 | <1% | 681 | $1K | |
| 93041 | <1% | 248 | $1K | |
| 82043 | <1% | 6,432 | $1K | |
| 86704 | <1% | 2,363 | $1K | |
| 96521 | <1% | 200 | $1K | |
| 86331 | <1% | 1,092 | $1K | |
| 86171 | <1% | 1,085 | $1K | |
| 85384 | <1% | 748 | $998.40 | |
| 49083 | <1% | 99 | $987.90 | |
| 0391 | <1% | 26 | $977.57 | |
| 93225 | <1% | 42 | $975.15 | |
| 87205 | <1% | 2,504 | $969.07 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,223 | $956.64 |
| J7518 | Mycophenolic acid, oral, 180 mg | <1% | 14 | $952.20 |
| 82378 | <1% | 259 | $929.56 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,951 | $927.23 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 636 | $922.03 |
| 87177 | <1% | 182 | $898.31 | |
| 83516 | <1% | 1,370 | $886.28 | |
| 83883 | <1% | 168 | $882.69 | |
| 83001 | <1% | 2,347 | $880.16 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 293 | $864.21 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 421 | $863.17 |
| 70547 | <1% | 74 | $827.34 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 44 | $823.76 |
| 93976 | <1% | 25 | $815.15 | |
| 43249 | <1% | 107 | $809.93 | |
| S9465 | Diabetic management program, dietitian visit | <1% | 13 | $801.58 |
| 74221 | <1% | 29 | $782.96 | |
| 80185 | <1% | 285 | $781.86 | |
| 85045 | <1% | 1,811 | $781.82 | |
| 84425 | <1% | 916 | $770.70 | |
| 95912 | <1% | 20 | $770.20 | |
| 80164 | <1% | 248 | $767.38 | |
| 93226 | <1% | 16 | $765.27 | |
| 74178 | <1% | 42 | $738.77 | |
| 86225 | <1% | 1,272 | $722.24 | |
| Z5406 | <1% | 58 | $710.95 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 303 | $690.61 |
| 86708 | <1% | 1,990 | $685.26 | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 29 | $682.53 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 115 | $678.56 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,764 | $671.72 |
| 86308 | <1% | 142 | $664.86 | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 128 | $655.97 |
| Z4303 | <1% | 14 | $645.45 | |
| 84207 | <1% | 281 | $636.30 | |
| 88720 | <1% | 228 | $635.21 | |
| 97161 | <1% | 1,143 | $611.47 | |
| 86160 | <1% | 398 | $586.63 | |
| 85460 | <1% | 233 | $577.45 | |
| 89051 | <1% | 450 | $576.89 | |
| 73560 | <1% | 274 | $574.43 | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 15 | $565.37 |
| 20610 | <1% | 303 | $564.29 | |
| 90619 | <1% | 98 | $563.28 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 158 | $553.21 |
| 82150 | <1% | 398 | $552.06 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 524 | $535.37 |
| 83002 | <1% | 1,532 | $533.61 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,732 | $524.71 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,050 | $520.32 |
| 71010 | <1% | 258 | $519.35 | |
| 0730 | <1% | 435 | $512.63 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 16 | $509.96 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 4,733 | $501.29 |
| 86039 | <1% | 537 | $492.39 | |
| 84165 | <1% | 416 | $489.64 | |
| 84145 | <1% | 504 | $485.36 | |
| 88341 | <1% | 37 | $466.67 | |
| 87338 | <1% | 1,608 | $464.87 | |
| 93321 | <1% | 168 | $462.39 | |
| J7517 | Mycophenolate mofetil, oral, 250 mg | <1% | 20 | $461.78 |
| 82952 | <1% | 2,263 | $459.99 | |
| 84520 | <1% | 1,574 | $435.68 | |
| 86430 | <1% | 1,367 | $426.02 | |
| 97163 | <1% | 61 | $418.50 | |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 45 | $414.52 |
| 87480 | <1% | 188 | $413.64 | |
| 87510 | <1% | 188 | $413.64 | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 88 | $413.19 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 664 | $409.23 |
| 74220 | <1% | 87 | $408.70 | |
| 0489 | <1% | 39 | $406.26 | |
| 81050 | <1% | 1,618 | $390.96 | |
| 94002 | <1% | 62 | $388.08 | |
| 84155 | <1% | 948 | $386.48 | |
| 92522 | <1% | 14 | $385.45 | |
| 72081 | <1% | 232 | $371.42 | |
| 86141 | <1% | 190 | $364.86 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 280 | $363.05 |
| J1270 | Injection, doxercalciferol, 1 mcg | <1% | 740 | $357.26 |
| 95718 | <1% | 37 | $355.26 | |
| 94645 | <1% | 263 | $352.81 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 14 | $351.64 |
| 87660 | <1% | 188 | $349.19 | |
| 88304 | <1% | 35 | $348.05 | |
| 96376 | <1% | 1,993 | $346.13 | |
| 76942 | <1% | 80 | $340.19 | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $340.00 |
| 82270 | <1% | 1,165 | $339.59 | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 29 | $334.35 |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | <1% | 65 | $332.50 |
| 74000 | <1% | 69 | $326.55 | |
| 82977 | <1% | 295 | $317.74 | |
| 87493 | <1% | 320 | $308.99 | |
| 82947 | <1% | 787 | $306.61 | |
| 86376 | <1% | 525 | $285.20 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 539 | $282.78 |
| 93015 | <1% | 26 | $279.86 | |
| 94620 | <1% | 35 | $279.77 | |
| 97802 | <1% | 55 | $276.59 | |
| 83520 | <1% | 570 | $274.68 | |
| 82240 | <1% | 83 | $274.35 | |
| 20611 | <1% | 139 | $270.50 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 36 | $267.84 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 706 | $267.67 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 182 | $261.71 |
| 77002 | <1% | 27 | $259.89 | |
| 99070 | <1% | 411 | $253.73 | |
| 86334 | <1% | 27 | $252.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 570 | $247.12 |
| 73000 | <1% | 42 | $243.65 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 18 | $242.70 |
| 71101 | <1% | 209 | $240.98 | |
| 86147 | <1% | 65 | $236.25 | |
| 84134 | <1% | 47 | $233.70 | |
| 86200 | <1% | 424 | $226.30 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 17 | $224.96 |
| 0361 | <1% | 16 | $222.18 | |
| 86800 | <1% | 245 | $222.08 | |
| 20553 | <1% | 77 | $205.31 | |
| 76641 | <1% | 27 | $201.92 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 183 | $199.57 |
| 0306 | <1% | 50 | $196.70 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 382 | $196.65 |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | <1% | 47 | $192.00 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 46 | $185.14 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 74 | $184.60 |
| 99153 | Mod sedat endo service >5yrs | <1% | 84 | $184.25 |
| 87581 | <1% | 73 | $183.01 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 92 | $180.93 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 32 | $176.26 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,024 | $173.34 |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 20 | $168.97 |
| 90656 | <1% | 113 | $168.44 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 568 | $166.91 |
| 84132 | <1% | 450 | $160.83 | |
| G0365 | Vessel mapping of vessels for hemodialysis access (services for preoperative vessel mapping prior to creation of hemodialysis access using an autogenous hemodialysis conduit, including arterial inflow and venous outflow) | <1% | 231 | $160.32 |
| 76881 | <1% | 12 | $148.83 | |
| G0008 | Administration of influenza virus vaccine | <1% | 13 | $145.50 |
| 96402 | <1% | 29 | $144.54 | |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | <1% | 51 | $137.60 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 73 | $135.30 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 288 | $127.54 |
| 86304 | <1% | 12 | $115.24 | |
| 95910 | <1% | 22 | $110.09 | |
| 20552 | <1% | 19 | $109.72 | |
| 43235 | <1% | 13 | $106.40 | |
| 87209 | <1% | 82 | $106.37 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 388 | $106.10 |
| 70220 | <1% | 14 | $105.76 | |
| 77280 | <1% | 31 | $104.83 | |
| 73100 | <1% | 48 | $99.62 | |
| 92134 | <1% | 131 | $98.70 | |
| 82810 | <1% | 29 | $97.20 | |
| 84480 | <1% | 70 | $97.09 | |
| 83010 | <1% | 44 | $95.52 | |
| 95819 | <1% | 14 | $93.25 | |
| 73070 | <1% | 32 | $87.00 | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 91 | $85.40 |
| 86255 | <1% | 562 | $81.58 | |
| 80177 | <1% | 70 | $81.57 | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 14 | $74.30 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 27 | $66.53 |
| 84300 | <1% | 116 | $66.18 | |
| 86146 | <1% | 13 | $66.00 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 25 | $62.01 |
| 95012 | <1% | 17 | $59.40 | |
| 73521 | <1% | 26 | $57.56 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 19 | $57.20 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $57.20 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 30 | $56.59 |
| 90714 | <1% | 268 | $55.19 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 19 | $50.78 |
| 82310 | <1% | 73 | $48.23 | |
| 0420 | <1% | 191 | $46.74 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 218 | $46.68 |
| 85613 | <1% | 37 | $45.87 | |
| 43450 | <1% | 15 | $45.60 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 217 | $43.46 |
| 20605 | <1% | 16 | $43.26 | |
| 87449 | <1% | 12 | $43.02 | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 48 | $38.43 |
| Q3014 | Telehealth originating site facility fee | <1% | 18 | $37.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 59 | $36.80 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 401 | $36.58 |
| A4657 | Syringe, with or without needle, each | <1% | 346 | $34.44 |
| 80306 | <1% | 12 | $33.04 | |
| 82652 | <1% | 107 | $30.00 | |
| 0255 | <1% | 62 | $29.20 | |
| 84075 | <1% | 41 | $28.58 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 144 | $28.50 |
| 96409 | <1% | 22 | $27.30 | |
| 20550 | <1% | 40 | $24.40 | |
| 84432 | <1% | 25 | $21.82 | |
| 0258 | <1% | 325 | $20.28 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 15 | $19.53 |
| 82436 | <1% | 12 | $18.76 | |
| 82010 | <1% | 155 | $15.68 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 42 | $13.90 |
| 85014 | <1% | 283 | $11.80 | |
| 83921 | <1% | 142 | $11.62 | |
| 99000 | <1% | 149 | $10.42 | |
| 83930 | <1% | 12 | $9.24 | |
| 77332 | <1% | 14 | $8.54 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 73 | $6.67 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 109 | $6.48 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 14 | $6.39 |
| 86880 | <1% | 14 | $5.17 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 13 | $4.96 |
| 81002 | <1% | 46 | $4.30 | |
| 90744 | <1% | 1,124 | $2.22 | |
| A4649 | Surgical supply; miscellaneous | <1% | 672 | $2.09 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 26 | $0.54 |
| 77417 | 0% | 60 | $0.00 | |
| 36416 | 0% | 121 | $0.00 | |
| 0250R | 0% | 472 | $0.00 | |
| 81000 | 0% | 146 | $0.00 | |
| 1036F | 0% | 59 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 127 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 85 | $0.00 |
| H2019 | Therapeutic behavioral services, billed per 15 minutes | 0% | 2,742 | $0.00 |
| 3008F | 0% | 33 | $0.00 | |
| 82330 | 0% | 25 | $0.00 | |
| 64484 | 0% | 15 | $0.00 | |
| 92250 | 0% | 25 | $0.00 | |
| 72158 | 0% | 13 | $0.00 | |
| H0049 | Alcohol and/or drug screening | 0% | 35 | $0.00 |
| 99366 | 0% | 16 | $0.00 | |
| 92551 | 0% | 163 | $0.00 | |
| 64483 | 0% | 33 | $0.00 | |
| 86870 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 49 | $0.00 |
| 90647 | 0% | 12 | $0.00 | |
| 72146 | 0% | 12 | $0.00 | |
| 82040 | 0% | 16 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 20 | $0.00 |
| G0010 | Administration of hepatitis b vaccine | 0% | 66 | $0.00 |
| 96549 | 0% | 42 | $0.00 | |
| 0370R | 0% | 195 | $0.00 | |
| 86618 | 0% | 13 | $0.00 | |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 17 | $0.00 |
| S5111 | Home care training, family; per session | 0% | 1,311 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 14 | $0.00 |
| 87902 | 0% | 539 | $0.00 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 12 | $0.00 |
| H0046 | Mental health services, not otherwise specified | 0% | 1,669 | $0.00 |
| 77295 | 0% | 33 | $0.00 | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | 0% | 50 | $0.00 |
| 0272R | 0% | 330 | $0.00 | |
| 90700 | 0% | 12 | $0.00 | |
| 76999 | 0% | 64 | $0.00 | |
| 92081 | 0% | 154 | $0.00 | |
| 0637 | 0% | 38 | $0.00 | |
| 0710R | 0% | 30 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 44 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 97 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 81 | $0.00 |
| 0681 | 0% | 25 | $0.00 | |
| 87901 | 0% | 18 | $0.00 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 14 | $0.00 |
| 4040F | 0% | 23 | $0.00 | |
| 95713 | 0% | 12 | $0.00 | |
| 97116 | 0% | 30 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 24 | $0.00 |
| 0302 | 0% | 25 | $0.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 67 | $0.00 |
| G9500 | Radiation exposure indices documented in final report for procedure using fluoroscopy | 0% | 18 | $0.00 |
| 96160 | 0% | 36 | $0.00 | |
| 84630 | 0% | 25 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWAGONER, CRAIG (CEO)
| Provider | Location | Paid |
|---|---|---|
| Fresno Community Hospital and Medical Center | Clovis, CA | $14.51M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $6.83M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $5.44M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $3.41M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $47K |
| Fresno Community Hospital and Medical Center | Fresno, CA | $45K |
| Clovis Community Medical Center | Clovis, CA | $12K |
| Fresno Community Hospital and Medical Center | Clovis, CA | $12K |
| Fresno Community Hospital and Medical Center | Fresno, CA | $10K |
| Fresno Community Hospital and Medical Center | Fresno, CA | $59.44 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.